KalVista Pharmaceuticals (KALV) EBITDA (2014 - 2025)

KalVista Pharmaceuticals (KALV) has 12 years of EBITDA data on file, last reported at -$59.0 million in Q3 2025.

• For the quarter ending Q3 2025, EBITDA fell 33.46% year-over-year to -$59.0 million; the trailing twelve-month figure through Jul 2025 stood at -$204.1 million (down 31.17% YoY), and the FY2025 full-year result was -$188.0 million, down 33.86% from the prior year.
• EBITDA eased to -$59.0 million in Q3 2025, from -$55.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$12.7 million in Q1 2021 to a low of -$59.0 million in Q3 2025.
• A 5-year average of -$32.4 million and a median of -$28.0 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA advanced 0.53% in 2021 and sank 110.82% in 2022, its largest moves.
• Tracing KALV's EBITDA over 5 years: stood at -$23.6 million in 2021, then slipped by 9.66% to -$25.9 million in 2022, then slipped by 14.92% to -$29.7 million in 2023, then slumped by 54.01% to -$45.8 million in 2024, then retreated by 28.81% to -$59.0 million in 2025.
• Business Quant data shows KALV's EBITDA at -$59.0 million in Q3 2025, -$55.0 million in Q2 2025, and -$45.8 million in Q4 2024.